ARS Pharmaceuticals Second Quarter 2024 Earnings: Misses Expectations

Simply Wall St

August 08, 2024

ARS Pharmaceuticals (NASDAQ:SPRY) Second Quarter 2024 Results

Key Financial Results

Net loss: US$12.5m (loss narrowed by 28% from 2Q 2023).
US$0.13 loss per share (improved from US$0.18 loss in 2Q 2023).

earnings-and-revenue-history — NasdaqGM:SPRY Earnings and Revenue History August 8th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

ARS Pharmaceuticals Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 25%. Earnings per share (EPS) also missed analyst estimates by 18%.

Looking ahead, revenue is forecast to grow 64% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are down 12% from a week ago.

Risk Analysis

We don't want to rain on the parade too much, but we did also find 2 warning signs for ARS Pharmaceuticals (1 makes us a bit uncomfortable!) that you need to be mindful of.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.